In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to ...

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid-2025.

Twenty months after being rocked by a clinical hold, MaaT Pharma has finally received the green light from the FDA to run a phase 3 trial of its pooled fecal therapy in gastrointestinal acute ...

LYON, France--(BUSINESS WIRE)--Regulatory News: These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also ...

LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT ...

MaaT Pharma is charting new territory in oncology by positioning microbiome-driven therapy as a potentially promising new pillar alongside traditional treatments. In this discussion, CEO and ...

In June 2025, the European Medicines Agency accepted for review the marketing authorization submission for this medicine MaaT Pharma will receive a €10.5 million upfront payment, further potential ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.